Cargando…

What is the Best Latent Structure of Negative Symptoms in Schizophrenia? A Systematic Review

BACKGROUND: Determining the best latent structure of negative symptoms in schizophrenia could benefit assessment tools, neurobiological research, and targeted interventions. However, no review systematically evaluated studies that assessed and validated latent models of negative symptoms. OBJECTIVE:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haguiara, Bernardo, Koga, Gabriela, Diniz, Elton, Fonseca, Lais, Higuchi, Cinthia H, Kagan, Simão, Lacerda, Acioly, Correll, Christoph U, Gadelha, Ary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Regular Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650068/ https://www.ncbi.nlm.nih.gov/pubmed/34901862 http://dx.doi.org/10.1093/schizbullopen/sgab013

Ejemplares similares

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

O1.4. HOW THE MOST CITED RESEARCH ARTICLES ABOUT SCHIZOPHRENIA IN 2018 DEPICT THE DISEASE?
por: Tonsig, Gabriela, et al.
Publicado: (2020)

Schizophrenia and COVID-19: risks and recommendations
por: Fonseca, Lais, et al.
Publicado: (2020)

Negative dimension stability across clinical stages and sociodemographic characteristics in schizophrenia
por: Koga, Gabriela, et al.
Publicado: (2022)

S129. DOES TREATMENT RESISTANT SCHIZOPHRENIA PRESENT A CHARACTERISTIC SYMPTOMATIC SIGNATURE?
por: Bertolucci, Bruno, et al.
Publicado: (2018)

T100. NICOTINE USE IMPACTS NEGATIVE SYMPTOMS SEVERITY IN SCHIZOPHRENIA
por: Oliveira, Hianna, et al.
Publicado: (2018)

Component mechanisms of executive function in schizophrenia and their contribution to functional outcomes
por: Berberian, Arthur A., et al.
Publicado: (2018)

Is semantic verbal fluency impairment explained by executive function deficits in schizophrenia?
por: Berberian, Arthur A., et al.
Publicado: (2016)

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA
por: Higuchi, Cinthia, et al.
Publicado: (2018)

T117. INVESTIGATION OF FORMAL THOUGHT DISORDER AND RESPONSE TO TREATMENT IN SCHIZOPHRENIA
por: Loures Malinowski, Fernando Rocha, et al.
Publicado: (2018)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

Latent Clinical-Anatomical Dimensions of Schizophrenia
por: Kirschner, Matthias, et al.
Publicado: (2020)

COVID-19 contamination and severity among patients with schizophrenia: Results from a specialized outpatient clinic survey
por: Costardi, Carlos Gustavo, et al.
Publicado: (2022)

S24. PATHWAYS LINKING ENVIRONMENTAL RISKS, POLYGENIC RISK SCORE TO SCHIZOPHRENIA AND PSYCHOTIC EXPERIENCES IN A BRAZILIAN COHORT OF CHILDREN AND ADOLESCENTS
por: Fonseca, Lais, et al.
Publicado: (2020)

M200. CLOZAPINE-INDUCED HEPATOTOXICITY: TWO CASE REPORTS
por: Dias, Cintia, et al.
Publicado: (2020)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

T97. CANNABIS USE IMPACTS SYMPTOM PRESENTATION IN ANTIPSYCHOTIC NAIVE PATIENTS IN FIRST EPISODE OF PSYCHOSIS (FEP)
por: Coutinho, Luccas, et al.
Publicado: (2018)

The association between adolescent suicide rates and socioeconomic indicators in Brazil: a 10-year retrospective ecological study
por: Jaen-Varas, Denisse, et al.
Publicado: (2019)

S128. CORRELATION OF DURATION OF UNTREATED PSYCHOSIS WITH TREATMENT RESPONSE ON THE SYMPTOM DIMENSIONS OF SCHIZOPHRENIA
por: Elias, Beatriz Yukie, et al.
Publicado: (2018)

Evaluation of the efficacy of transcranial direct current stimulation in the treatment of cognitive symptomatology in the early stages of psychosis: study protocol for a double-blind randomized controlled trial
por: Rabanea-Souza, Thais, et al.
Publicado: (2019)

O12.8. LOWER FAMILY INCOME PREDICTS PSYCHOTIC EXPERIENCES IN A COMMUNITY SAMPLE OF YOUTHS IN BRAZIL: RESULTS FROM A 3-YEAR FOLLOW-UP STUDY
por: Fonseca, Lais, et al.
Publicado: (2018)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

What Is the Best Approach to Treating Schizophrenia in Developing Countries?
por: Patel, Vikram, et al.
Publicado: (2007)

Neuropsychological correlates of remission in chronic schizophrenia subjects: The role of general and task-specific executive processes
por: Rabanea-Souza, Thais, et al.
Publicado: (2016)

S193. EFFICACY AND SAFETY OF TRANSCRANIAL DIRECT CURRENT STIMULATION FOR TREATING NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: THE FOLLOW-UP PHASE
por: Valiengo, Leandro, et al.
Publicado: (2020)

F91. ASSOCIATION BETWEEN SYMPTOM DIMENSIONS AND EXECUTIVE FUNCTION IN SCHIZOPHRENIA
por: Franco, Ana Luiza, et al.
Publicado: (2018)

Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia
por: Kubota, Manabu, et al.
Publicado: (2022)

Your Best Life: Resiliency and the Art of Medicine
por: Ring, David, et al.
Publicado: (2018)

More on the Best Evolutionary Rate for Phylogenetic Analysis
por: Klopfstein, Seraina, et al.
Publicado: (2017)

M184. SOCIAL SKILLS TRAINING FOR TREATMENT-RESISTANT SCHIZOPHRENIA WITH PREDOMINANTLY NEGATIVE SYMPTOMS
por: Kayo, Monica, et al.
Publicado: (2020)

What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?
por: Kemp, Aaron S., et al.
Publicado: (2010)

Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6‐week, randomized, double‐blind, placebo‐controlled study
por: Iyo, Masaomi, et al.
Publicado: (2021)

T51. TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA WITH TRANSCRANIAL CURRENT STIMULATION (TDCS): RESULTS OF RANDOMIZED, DOUBLE-BLINDED, SHAM-CONTROLLED TRIAL
por: Valiengo, Leandro, et al.
Publicado: (2018)

The Latent Structure of Negative Symptoms in the General Population in Adolescence and Emerging Adulthood
por: Havers, Laura, et al.
Publicado: (2022)

The Puzzle of Functional Recovery in Schizophrenia-Spectrum Disorders—Replicating a Network Analysis Study
por: Moura, Bernardo Melo, et al.
Publicado: (2022)

Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?
por: Keefe, Richard S. E., et al.
Publicado: (2013)

Abnormal visuomotor processing in schizophrenia
por: Robson, Siân E., et al.
Publicado: (2015)

Study of Novel Autoantibodies in Schizophrenia
por: Whelan, Ruth, et al.
Publicado: (2018)

Neurocognitive normality in schizophrenia revisited
por: Heinrichs, R. Walter, et al.
Publicado: (2015)

The search for healthy schools: A multilevel latent class analysis of schools and their students
por: Allison, Kenneth R., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_01lmosbml2a6j1ekar2h66r7v2